Telaglenastat is a GLS1 inhibitor with antitumor activity across various tumors, including renal cell carcinoma, triple‐negative breast cancer, non‐small cell lung cancer and lymphoma. Here, GLS is linked to hereditary clear cell renal cell carcinoma.